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  Abstract 
    Objectives.   The aim of this study was to compare patients  ’   preference for olanzapine orodispersible tablet (ODT) with oral 
conventional tablet (OCT).   Methods.   A 12-week randomized, crossover, multinational, open-label study was conducted to 
estimate the proportion of patients preferring ODT or OCT. Outpatients with stable schizophrenia on OCT monotherapy 
were randomly assigned 1:1 to ODT or OCT. Compliance and drug attitude were measured using the Drug Attitude 
Inventory (DAI-10) and Medication Adherence Form (MAF) scales; tolerability and safety by Association for Methodology 
and Documentation in Psychiatry (AMDP-5) questionnaire and adverse event summary.   Results.   A total of 175 patients 
answered a preference question: 106 (61%) preferred ODT and 48 (27%) preferred OCT (  P       0.001 adjusted for treatment 
sequence); 21 (12%) expressed no preference. There was no signiﬁ  cant change in DAI-10 with either formulation. MAF 
was above 75% in 94% vs. 93% of patients on ODC and OCT, respectively. Compliance as measured by tablet count was 
above 98% on both formulations. The adverse event proﬁ  les did not differ between formulations. Mean weight increase 
over 6 weeks on ODT was 0.8 kg and on OCT was 0.6 kg.   Conclusions.   Given the importance of patients  ’   preference for 
treatment planning and success, the ODT formulation should be routinely considered as a treatment option.   
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    Introduction 
  Active patient participation in therapeutic decision-
making is generally viewed as a precondition to pos-
itive health outcomes (Street 2007). A greater 
understanding of patients  ’   preferences for new for-
mulations of treatment is central to current models 
of shared patient-doctor decision making and has 
gained considerable interest in scientiﬁ  c research by 
applying open-label crossover, sequential trials (Voss 
and Klapper 2002; Dowson and Almqvist 2005; 
Nausieda et al. 2005; Slevin and Ryan 2006). 
Patients  ’   preference is both clinically and ﬁ  nancially 
important, as it can have long-term implications in 
terms of patients  ’   motivation and insight into their 
disease state and its treatment, which might have a 
direct impact on the patient’s compliance and treat-
ment adherence (Kassirer 1994; Jahng et al. 2005). 
A recent systematic review (Preference Collaborative 
Review Group 2008) found that patients  ’   preference 
has an inﬂ  uence on study outcomes: patients who 
were randomized to their preferred treatment had a 
standardized effect size greater than those who were 
indifferent to their treatment assignments. However, 
some studies have not found a correlation between 
patient preferences and outcome (McKay et al. 1995; 
Ward et al. 2000). An analysis of treatment outcomes 
for depressed patients found that patients who 
received their preferred treatment option did better 
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preference. An open-label design was selected since 
blinding would eliminate the possibility for patients 
stating their preference for a speciﬁ  c  formulation 
based on its physical characteristics.     
  Study design 
  This 12-week, open-label, randomized, crossover 
multinational study was conducted to estimate the 
proportion of patients preferring ODT or OCT 
after 6 weeks of treatment with each formulation. 
The study started in May 2006 and was conducted 
in ﬁ  ve countries (Brazil, Israel, Mexico, Romania 
and Turkey) at 19 investigational centers. All patients 
were outpatients, including patients in day hospitals. 
The study consisted of three periods (Figure 1). 
Period I was a 4-week screening phase for eligibility. 
At the beginning of period II, patients were ran-
domly assigned in a 1:1 ratio to ODT or OCT at a 
dose of 5  –  20 mg in both arms. Randomization was 
using computer generated randomization sequence. 
The starting dose was at the discretion of the treating 
physician and could be adapted to patient needs dur-
ing period II. At the start of period III, patients were 
switched to the alternative formulation (i.e. patients 
receiving ODT switched to OCT and patients receiv-
ing OCT were switched to ODT), but remained at 
the dose they received at the end of period II.    
  Study population 
  Participants were eligible for the study, if they 
were aged 18  –  65 years, stable with respect to their 
(mean difference in Beck Depression Inventory Score 
4.6, 95% CI: 0.0  –  9.2) than those who were randomly 
assigned to treatment (Chilvers et al. 2001). The 
Clinical Antipsychotic Trial of Intervention Effective-
ness (CATIE) also showed that more positive atti-
tudes towards medication may improve outcomes 
(Mohamed et al. 2008). As patient preference for 
medication may inﬂ  uence outcomes, there is a need 
for patient preference studies in mental health 
research   (  Howard and Thornicroft 2006). 
  There is a small number of clinical trials where 
patients  ’   preferences for different formulations of the 
same drug have been studied. (M  ü  ller 2006). Ques-
tionnaire survey revealed that high preference for 
oral applications, particularly conventional tablets 
and capsules among psychiatric inpatients and staff 
members of a psychiatric department. 
  In other therapeutic areas, the preferences of 
patients with allergic rhinitis demonstrated the pref-
erence of the fast-dissolving tablet formulation 
(Roger et al. 2008). Another study concluded that 
capsule odour, difﬁ   culty swallowing, taste, breath 
odour had an impact on patients  ’   preference for 
choosing drug formulation of two types of cyclos-
porine capsules (Steinberg et al. 2003). These results 
indicate that the characteristics of the formulation 
may play an important role in preference. However, 
patients  ’   acceptability and preference for the ODT 
relative to the OCT formulation of olanzapine has 
not been investigated. 
  In order to aid clinical decision making, this study 
aimed to determine the formulation preference of 
patients with schizophrenia regarding ODT and 
OCT and to elucidate factors associated with this 
Screening Period
(Study Period I)
Study Period II Study Period III
All Patients
olanzapine orodispersible
5–20 mg/day
olanzapine tablet 5–20 mg/day olanzapine tablet 5–20 mg/day
4 weeks
Randomization Crossing Over
6 weeks
Visit 1 Visit 4 Visit 7 Visit 0
Biweekly visits Biweekly visits
Visit 2 Visit 3 Visit 5 Visit 6
6 weeks
olanzapine orodispersible
5–20 mg/day P
r
e
f
e
r
e
n
c
e
s
   
Figure 1.         Study design: A 12-week, randomized, crossover, multinational, open-label study.   896     I. Bitter et al.     
The patients  ’   subjective attitude to medication was 
measured by using the Drug Attitude Inventory 
DAI-10 scale (Hogan et al. 1983). Its total score 
comprises values from   –  10 to 10 with higher scores 
indicating more positive attitude towards medica-
tion. We used the score to examine how the attitude 
of patients with schizophrenia towards their medica-
tions may affect compliance. The DAI scale has been 
intensively used to investigate patient attitudes for 
oral antipsychotics (Hofer et al. 2002; Freudenreich 
et al. 2004; Day et al. 2005; Adewuya et al. 2006; 
M  ü  ller 2006) as well as on attitudes and preferences 
for oral with regard to depot medications (Heres 
et al. 2007; Patel et al. 2009). Patients  ’   clinical sever-
ity status was assessed using the Clinical Global 
Impression of Severity (CGI-S) scale for every study 
visit. Medication adherence was estimated by using 
the Medication Adherence Form (MAF) (Swartz 
et al. 2001). MAF is a single item   “  global judgment 
of medication adherence  ”   completed by the person 
administering the scale, based on detailed question-
ing of the patient, or any other available source (e.g., 
family). Based on that information, the rater makes 
a global judgment of the time (almost never: 0  –  25%, 
sometimes: 26  –  50%, usually: 51  –  75%, almost always: 
76  –  100%) the patient took the medication as pre-
scribed since the last visit. Safety and tolerability of 
ODT versus OCT was measured by the AMDP-5 
(Bobon and Woggon 1986). Standard laboratory 
tests measuring prolactin, liver function, blood bio-
chemistry, whole blood count and ECG were per-
formed. Furthermore, a physical examination of all 
patients was completed, which included height and 
weight. In order to follow up on appetite changes, a 
visual analogue scale (VAS) was used in all the visits 
starting from randomization (Gift 1989). The scale 
is a line with anchors at each end to indicate the 
extremes of the patient’    s hunger sensations in the 
study with values between 0 and 100. In our study, 
we measured appetite from most versus least and the 
patients had to check on the line where his/her appe-
tite level was in the visual analogue scale.     
  Statistical methods 
  The sample size for this study was calculated using 
the Mainland-Gart method (Senn 1993) for cross-
over trials based on a chi-square test that allowed for 
treatment sequence effects. The calculation was 
based on 80% power and 5% signiﬁ  cance level as 
well as on the assumption of 60% preference for one 
of the two formulations and 10% rate for patients 
who express no preference or dropped out. The pri-
mary objective analysis utilized data from all patients 
without major protocol violations (per protocol set) 
who experienced both formulations on the study 
symptoms of schizophrenia according to DSM-IV 
(APA 1994) or DSM-IV-TR (APA 2000) for at 
least 4 weeks before screening (visit 0), and able to 
take ODT or OCT formulations at dose 5  –  20 mg/
day as prescribed by the treating physician. All 
patients used OCT as antipsychotic monotherapy 
for at least 1 month before screening, and then con-
tinuously until randomization. For those patients 
who were using OCT before the randomization in 
doses higher/lower than allowed by the protocol, 
the dose was adapted in a range from 5  –  20 mg. 
  Patients were excluded from participation in the 
trial if previous treatment with olanzapine was inef-
ﬁ  cient and if they had a signiﬁ  cant suicide risk, sub-
stance abuse or dependency. Also, patients with an 
unstable general medical condition, including history 
of seizures, uncorrected narrow-angle glaucoma, leu-
copenia, diabetes, acute systemic infections, unstable 
cardiovascular disorders, with abnormal laboratory 
values or if they were human immunodeﬁ  ciency virus 
positive, were excluded. Pregnancy and breastfeeding 
were also exclusion criteria. Patients having Clinical 
Global Impression of Severity (CGI-S) score (Guy 
1976)      4 at Visit 0 and Visit 1; CGI-S score increase 
by one or more points between Visit 0 and Visit 1, or 
being considered as noncompliant with their previous 
antipsychotic medication according to physician 
opinion, were also excluded. Patients who were inves-
tigator site personnel directly afﬁ  liated with the study, 
or were immediate family of investigator site person-
nel and employees of the sponsor (Eli Lilly and Com-
pany) could not take part in the study. 
  This study was conducted according to the ethical 
principals stated in the Declaration of Helsinki. Eth-
ical approval for the protocol was obtained from the 
institutional review board for each study site, and all 
participants (or equivalent appropriate legal author-
ity) gave written informed consent for participation 
in the trial.     
  Outcome measures 
  All patients who completed or discontinued the 
study after trying both formulations were asked to 
express their preference. This was the primary out-
come variable and it was assessed by a three-choice 
question, which study investigators explored with 
their patients and recorded in the data report form. 
The question was formulated as:   “  Based on your 
patient’s experience with both olanzapine forms in 
the study, which form of medication would your 
patient prefer to take in the future?  ”   As an answer 
they could select: OCT or ODT, or refuse to express 
any preference. Patients were also asked to specify 
the reason for preference. There was no structured 
questionnaire for the preference reasons provided.      Oral olanzapine formulation preference            897
is established and reported in the European Union 
Summary of Product Characteristics (EMEA Zyprexa 
Product Information 2008). Concomitant medica-
tions with primarily central nervous system activity 
(including other antipsychotics) were not allowed 
except for antidepressants other than ﬂ  uvoxamine 
and monoamine oxidase (MAO) inhibitors and anti-
convulsants, provided that a stable dose was given for 
at least 2 months prior to study entry and throughout 
study periods II and III. Concomitant medication use 
was recorded at each scheduled visit.       
  Results   
  Patients 
  As presented in the patient ﬂ  ow diagram (Figure 2), 
297 patients were screened, 32 failed screening, 265 
patients from 5 countries (Brazil [  N    52], Israel 
[  N    20], Mexico [  N    49], Romania [  N    42], and 
Turkey [N      102]) entered the study and were ran-
domly assigned to ODT or OCT formulation. One 
hundred and thirty patients started with ODT for-
mulation and 135 started with OCT formulation. Of 
265 patients enrolled, 207 were included in the per 
protocol analysis set. Fifty eight patients (29 in each 
group) were excluded due to protocol violations. The 
major protocol violations were the following: no 
signed informed consent, unstable disease, patients 
not taking study medication or taking additional 
antipsychotic drugs, and taking ODT instead of 
OCD before the study. Out of 207 patients, 26 
patients discontinued during study period II and six 
during period III. The most frequent reasons for dis-
continuation were lost to follow-up (13 patients), 
followed by sponsor decision (seven patients) and 
patient decision (ﬁ  ve patients). The most frequent 
diagnosis was paranoid schizophrenia (160 [77%] 
patients) followed by undifferentiated schizophrenia 
(26 [13%]). Almost one-third of the patients (64 
[31%]) had a history of hospitalization in the last 2 
years, and 78 (38%) patients had a family history of 
schizophrenia. A high proportion of patients in the 
ODT group (41 [41%]) and in the OCT group (48 
[45%]) entered the study with pre-existing condi-
tions, where obesity was the most common (16 
[16%] patients and 24 [23%] patients in ODT and 
OCT groups, respectively). Further baseline charac-
teristics of the per-protocol analysis set are presented 
in Table I.     
  Treatment patterns and concomitant medications 
  Patients had to use OCT formulation (as monother-
apy) for at least 1 month before the study entry to be 
eligible to enter screening for the trial. Retrospective 
and expressed a preference for one of the two treat-
ments received. The chi-square test determined 
whether treatment sequence and preference were 
associated, allowing to evaluate the preference adjust-
ing for possible treatment sequence effects. Treat-
ment sequence effect refers to the order in which the 
patients are receiving different formulations of the 
study medication. Patients who expressed no prefer-
ence, or did not complete the ﬁ  nal preference assess-
ment, were excluded from the analysis. We also 
looked for an association between formulation pref-
erence and baseline patient characteristics: age, sex, 
ethnic origin, smoking status, type of diagnosis, 
duration of diagnosis, hospitalisation, family history, 
education, employment, marital and housing status, 
weight, CGI-S, DAI-10, VAS, MAF, and country 
effect using logistic regression models. Efﬁ  cacy 
(CGI-S) was evaluated not only at endpoints but at 
each study visit and compared between the ODT 
and OCT patients using the repeated measurements 
ANCOVA model adjusted for treatment sequence 
and sequence by treatment interaction effect as well 
as MAF score. To better satisfy the assumptions of 
the analyses, the logarithmic transformation was 
applied to the CGI-S scores. The MAF and DAI-10 
scores at endpoints were analyzed using a similar 
ANCOVA approach with adjustment for signiﬁ  cant 
baseline covariates. Safety analyses were performed 
on all patients receiving at least one dose of study 
drug after randomization. Safety and tolerability 
was recorded by the AMDP-5 scale; in addition, 
VAS subjective appetite assessment, laboratory val-
ues, weight and vital sign measures were compared 
between ODT and OCT using ANOVAs with treat-
ment sequence effect as a covariate. Non-normally 
distributed responses were log-transformed prior to 
analyses. The difference of weight and BMI from 
baseline to endpoint in the two treatment groups 
was calculated. The weight comparison was repeated 
for completers to ensure equal duration on each for-
mulation and per weeks on study to adjust for dura-
tion effect in all patients. McNemar  ’  s test was used 
for the comparison of the number of patients with 
at least one adverse event (AE) between formula-
tions. Study AEs were deﬁ  ned as any AE with the 
start date occurring after randomization.     
  Study medications 
  Both olanzapine ODT and OCT formulations were 
used in this study as 5-, 10- or 20-mg tablets, admin-
istered orally once daily, preferably in the evening. 
Five to 20 mg/day of oral olanzapine dose is the 
documented effective range and it reﬂ  ects the dose 
range in general clinical practice. ODT formulation  ’  s 
equivalence with the conventional olanzapine tablet 898     I. Bitter et al.     
(visit 0), all 207 (100%) patients were on olanzapine 
treatment, of which 173 (84%) were on olanzapine 
monotherapy. 
  The mean dose throughout the study was 12.3 
mg/day for ODT and 12.4 mg/day for OCT. Forty-
eight (24%) patients were receiving the maximum 
dose allowed of 20 mg/day. Information about con-
comitant medications was collected at each of the 
three study periods. During the ﬁ  rst  treatment 
period (visits 1 to 4), there were 12 (12%) patients 
in the ODT group and 20 (19%) patients in the 
OCT group using concomitant medications. In the 
medication history showed that, during the last 
2 years, patients used a variety of medication treat-
ments before they started with the OCT formulation. 
Forty-four (21%) patients had no previous antipsy-
chotic treatment for the past 2 years prior to the olan-
zapine treatment; four (2%) patients were using 
olanzapine monotherapy, ﬁ  fteen (7%) used olanza-
pine and one other medication; 77 (37%) patients 
used one non-olanzapine medication only; 66 (32%) 
patients used two or more non-olanzapine medica-
tions; and one patient was never treated in the past 
prior to current olanzapine treatment. At study entry 
Screened 297
Failed screening 32
Randomized 265
Started with OCT 135
Entered period II OCT 106
Protocol violation 29
Discontinued 12 Discontinued 14
Switched to OCT 87 Switched to ODT 94
Discontinued 5 Discontinued 1
Completed period III on
OCT 86
Completed period III on
ODT 89
Started with ODT 130
Entered period II ODT 101
Protocol violation 29
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when ODT was taken ﬁ   rst during the crossover 
study, the preference for it was higher than for OCT 
at the end of the study. In summary, these data sug-
gest that the impact of the experience of patients on 
the last formulation taken was not strong enough to 
overcome the formulation preference results.     
  Secondary measures 
  Patients had to be stable on olanzapine to be eligible 
for the study. Disease severity, measured by CGI-S, 
could not increase and had to remain as 4 points or 
less during screening to be eligible for randomiza-
tion. CGI-S remained stable throughout the study: 
at randomization mean CGI-S for ODT was 2.3 
[Standard Deviation (SD) 0.75]; for OCT 2.5 [SD 
0.73], at the end of the ﬁ  rst 6 weeks period mean 
CGI-S for ODT remained at 2.3 [SD 0.73] and for 
OCT 2.4 [SD 0.76]. After the switch to the other 
formulation, patients remained stable: at the end of 
the study in the group which changed from OCT to 
ODT, the mean CGI-S was 2.4 [SD 0.72] and in 
the group which changed from ODT to OCT mean 
CGI-S was 2.2 [SD 0.81]. Results of a repeated 
measures ANCOVA, adjusted for compliance 
(MAF), did not indicate any difference in efﬁ  cacy 
between treatment formulations (  P       0.87). No sig-
niﬁ   cant change in subjective experience with the 
medication was found as measured by DAI-10: mean 
increase 0.2 on ODT [SD 1.76], 0.0 on OCT [SD 
1.57]. The ANCOVA adjusted for patient baseline 
characteristics did not indicate a difference between 
treatment formulations (  P       0.29). A medication 
adherence above 75% as measured and deﬁ  ned by 
MAF scale was found in 182 (94%) versus 179 
(93%) patients on ODC and OCT, respectively. No 
patients were less than 50% adherent at any time on 
any formulation. Compliance measured by tablet 
count was above 98% for both formulations. Hous-
ing status had the strongest association with compli-
ance ( P       0.001): compliance in patients in supervised 
ODT group, all 12 patients used 12 different med-
ications, including diazepam, bromazepam, capto-
pril and carbamazapine, among others. The most 
commonly used concomitant medications in the 
OCT group were diazepam (5 [4.7%]), glibencl-
amide (2 [1.9%]), valproic acid (2 [1.9%]), hydro-
chlorothiazide (2 [1.9%]), and simvastatin (2 
[1.9%]). After the crossover (visits 4  –  7), in the group 
changing from OCT to ODT, 19 (19%) patients 
continued concomitant medications, and 11 (10.4%) 
took concomitant medications in the group chang-
ing from ODT to OCT.     
  Preference results 
  Signiﬁ   cantly more patients preferred ODT over 
OCT. One hundred and seventy-ﬁ  ve  patients 
answered the preference question: 85 patients from 
the group which started with ODT formulation and 
90 from the group which started with OCT formu-
lation. Overall, 106 patients (61%) preferred ODT 
and 48 (27%) preferred OCT (p     0.001 adjusted for 
treatment sequence); 21 (12%) patients expressed 
no preference. Patient preference by treatment peri-
ods are provided in Table II. None of the baseline 
factors explored had a statistically signiﬁ  cant asso-
ciation with the formulation preference expressed. 
  As a secondary ﬁ   nding, it was observed that a 
higher percentage of patients (57%) would prefer to 
take, in the future, the formulation from period III 
rather than switch back to the formulation from 
period II. If patients start with ODT, only 47% pre-
ferred ODT formulation versus 39% who preferred 
OCT indicating the shift from overall preferences 
towards the last formulation. Similarly, of the patients 
who started with OCT, only 17% preferred OCT 
and 73% preferred ODT indicating similar shift 
towards the last formulation. If there was no sequence 
effect independently from what they started with, 
similar proportions would prefer the same formula-
tion (about 27% OCT and 61% ODT). But even 
Table I. Demographic characteristics of patients in primary and 
secondary analyses
All patients
Started from 
ODT
Started from 
OCT
Total, N (%) 207 (100) 101 (100) 106 (100)
Sex, male, N (%) 131 (63.3) 61 (60.4) 70 (66.0)
Caucasian, N (%) 131 (63.3) 66 (65.3) 65 (61.3)
Hispanic, N (%) 54 (26.1) 24 (23.8) 30 (28.3)
Other, N (%) 22 (10.6) 11 (10.9) 11 (10.4)
Age, mean   SD 35.3   11.1 35.2   10.4 35.5   11.8
Weight, kg, 
mean   SD
75.0   14.9 73.2   14.3 76.8   15.3
BMI kg/m2, 
mean   SD
26.9   5.0 26.5   5.0 27.3   4.9
Table II. Patient preference for olanzapine formulation by 
treatment sequence.
All, N (%)
Started from 
ODT, N (%)
Started from 
OCT, N (%)
Total preference 175 (100) 85 (100) 90 (100)
Preference period II 55 (31.4) 40 (47.1)∗ 15 (16.7)∗
Preference period III 99 (56.6) 33 (38.8)∗ 66 (73.3)∗
No preference 
expressed
21 (12.0) 12 (14.1) 9 (10.0)
∗P 0.001 from chi-square test for preference by treatment 
sequence association indicates difference in preference between 
formulations. Patients who expressed no preference were excluded 
from the test.900     I. Bitter et al.     
origin, smoking status, type of diagnosis [paranoid 
vs. others], duration of diagnosis, recent hospital-
ization, family history, education, work, marital 
status, housing status, baseline weight and BMI, 
drug attitude, VAS scale [appetite scale], compli-
ance, or country of residence) had a statistically 
signiﬁ  cant association with the formulation prefer-
ence expressed. The generalizability of the results 
is limited to stable adherent patients with schizo-
phrenia without substantial comorbid issues who 
can do well on olanzapine monotherapy between 
doses of 5  –  20 mg/day; however, it was important to 
test formulation preference in stable patients to 
avoid interaction of their judgement with symptom 
improvement. Although data suggesting that patient 
preference can be correctly and reliably measured 
by a single preference question, this method is not 
a standardized measure. 
  This is the ﬁ  rst multicenter, large-scale, random-
ized trial in psychiatry to assess preferences for these 
two oral formulations of olanzapine in patients who 
were treated in a manner similar to common clinical 
practice. The open-label, crossover design is an 
accepted or established method in the literature to 
compare formulation preference. There is data sug-
gesting that patient preference can be correctly and 
reliably measured by a single preference question 
(Allain et al. 2003). 
  The effectiveness of OCT in the treatment of 
patients with schizophrenia is widely investigated in 
several randomized, controlled trials and in observa-
tional studies as well, for example, the Effectiveness 
of Antipsychotic Drugs in First-Episode Schizo-
phrenia and Schizophreniform disorder (EUFEST) 
trial (Kahn et al. 2008), the CATIE trial (Lieberman 
et al. 2005), the Schizophrenia Outpatient Health 
Outcomes studies (Novick et al. 2007; Bitter et al. 
2008; Dossenbach et al. 2008) and in a recent 
meta-analysis (Leucht et al. 2009). In recent years, 
more clinical attention has been paid to oral dis-
persible formulation of medications including ODT. 
Pharmacokinetic studies have shown that olanzap-
ine ODT is bioequivalent to OCT with the same 
rate and extent of bioavailability (Bergstrom et al. 
2004). 
residence or being homeless was lower than in patients 
with independent residence. Free text comments 
about the preference reasons for both formulations 
were collected. Common reasons for preference of a 
speciﬁ  c formulation, as indicated by patients, were 
ease of use, taste of the formulation, expectation of 
better effectiveness and weight change.     
  Safety results 
  The safety population included all the patients who 
received at least one dose of study medication at 
some time in the study. Two-hundred and ﬁ  fty 
patients who received ODT treatment and 248 
patients who received OCT treatment were ana-
lyzed for the safety data. The total number of patients 
with at least one AE while treated with ODT was 
42 (16.8%) and with OCT 31 (12.5%) (  P       0.31) 
(Table III). Thirty-two (12.8%) patients receiving 
ODT treatment and 24 (9.7%) receiving OCT 
treatment (  P       0.33) experienced at least one AE 
related to study drug (as described by investigators). 
The most common adverse events in the safety pop-
ulation were: weight increase (ODT 19 [7.6%]; 
OCT 15 [6.0%]), somnolence (ODT 4 [1.6%]; 
OCT 5 [2.0%]), and, hypertriglyceridemia (ODT 6 
[2.4%] patients; OCT 3 [1.2%] patients). Mean 
weight increase over 6 weeks in the ODT group was 
0.8 kg [SD 2.29] and in the OCT group 0.6 kg [SD 
1.97]. There were two serious adverse events (SAEs) 
reported in this study: appendicitis and completed 
suicide. None of those SAEs were considered as 
related to study drug by the investigators. According 
to the AMDP-5 scale, safety and tolerability did not 
differ between formulations. Changes in appetite as 
measured by the visual analogue scale (VAS) did not 
reveal a consistent pattern (mean change in ODT 
  –  0.1 [SD 14.9]; in OCT 2.0 [SD 14.7]).       
  Discussion 
  Most of the patients who answered the preference 
question declared they preferred ODT over OCT. 
None of the baseline factors explored (age, sex, 
Table III. Number of patients with adverse events by treatment and study period (safety population).
Started from ODT Started from OCT Pooled by treatment
AEs by MedDRA version 9.1
Period II 
(ODT)
Period III 
(OCT)
Period II 
(OCT)
Period III 
(ODT) ODT OCT
Total patients treated, N (%) 130 (100) 116 (100) 135 (100) 120 (100) 250 (100) 248 (100)
Total patients with at least 
one AEs, N (%)
27 (20.8) 7 (6.0) 24 (17.8) 15 (12.5) 42 (16.8)∗ 31 (12.5)∗
∗P   0.3.     Oral olanzapine formulation preference            901
analysed statistically since the question was not 
designed accordingly and answers, therefore, repre-
sent a collection of single personalized reasons. It 
was also a possible ground for bias that the formula-
tion considered to be more technologically advanced 
was also preferred and perhaps this perception, if it 
existed, may also explain the preference for ODT in 
the current study. 
  Although several papers and communications 
have reported possible weight reduction or less 
weight gain when patients start or switch to ODT, 
as contrasted with OCT (Karagianis et al. 2008), 
our study did not ﬁ  nd meaningful differences in this 
regard. However, this study was not powered to 
detect weight differences.     
  Conclusion 
  Most of the patients who answered the preference 
question declared they preferred olanzapine orodis-
persible over olanzapine conventional formulation. 
The olanzapine orodispersible tablet formulation 
should be considered a useful alternative to classical 
conventional olanzapine in appropriate patients, if 
patient preference is taken into account. The impact 
of formulation preference on long-term adherence 
warrants further investigation.   
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  Moreover, the orodispersible formulation of olan-
zapine is well accepted and effective in acute settings 
and demonstrated signiﬁ  cant improvement in Posi-
tive and Negative Symptoms Scale (PANSS) total 
score in a 6-week open-label study with acutely ill 
psychotic patients who used ODT formulation 
(Kinon et al. 2003). In this trial, by week 6, 60% of 
patients were considered responders and the study 
authors concluded that the ODT formulation of 
olanzapine was effective in the rapid reduction of 
psychopathology. In an observational study, two 
patient groups receiving ODT or OCT showed sim-
ilar effectiveness after 2 weeks (Czekalla et al. 2007). 
Another study conﬁ  rmed the effectiveness of ODT 
formulation as measured by Positive and Negative 
Symptoms Scale Excitement Component score 
(PANNS-EC) for the treatment of acute agitated 
patients in a naturalistic, open-label study (Pascual 
et al. 2007). A study by Dardennes et al., with 62.4% 
of poorly compliant or noncompliant patients, con-
cluded that those patients who received the ODT 
formulation had an effective reduction of psychotic 
symptoms (Dardennes et al. 2004). An outpatient 
study in schizophrenia or schizoaffective disorder 
(  n       174) showed that use of the ODT formulation 
could increase compliance (Dilbaz et al. 2006). The 
recent review of ODT formulation publications 
(San et al. 2008) conﬁ  rmed that orally disintegrat-
ing olanzapine is an effective atypical antipsychotic 
with an acceptable safety proﬁ  le and can reduce the 
burden of treatment on patients and caregivers due 
to its ease of administration. Although most patients 
preferred ODT over OCT in our trial, our study did 
reveal an association between preference and treat-
ment sequence whereby patients more frequently 
indicated that they would rather continue the cur-
rent formulation than go back to the previous one. 
The fact that only 12% of patients did not show 
preference to the different formulations suggests 
that preference can be assessed in clinical settings 
and formulation does matter to patients. 
  The main objective of the study was to compare 
patients  ’   preference for the available oral formula-
tions of olanzapine, so the study was not powered to 
address the secondary objectives such as differences 
between formulations in outcomes such as CGI-S, 
compliance, drug attitude, weight, or others. It is still 
an open question whether this short-term preference 
favoring the ODT formulation could result in better 
adherence in longer-term treatment. The study was 
an open-label randomized study, as blinding was not 
appropriate since preference was related to the phys-
ical characteristics of the formulations themselves. 
Collected and grouped reasons might reﬂ  ect patients  ’   
expectations rather than ease of use and taste of the 
formulation, but the former information cannot be 902     I. Bitter et al.     
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